Xenon Pharmaceuticals Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
XENE$41.39+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars except share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $199,163 | $142,712 |
| Marketable securities (note 5) | 349,723 | 484,193 |
| Other receivables | 1,371 | 1,469 |
| Prepaid expenses and other current assets | 10,392 | 6,890 |
| Total current assets | 560,649 | 635,264 |
| Marketable securities, long-term (note 5) | 37,152 | 127,496 |
| Operating lease right-of-use asset, net (note 7) | 6,626 | 7,939 |
| Property, plant and equipment, net (note 6) | 8,721 | 10,278 |
| Deferred tax assets (note 14) | 12,864 | 9,666 |
| Prepaid expenses, long-term | 7,151 | 7,496 |
| Total assets | $633,163 | $798,139 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (note 8) | $40,260 | $34,221 |
| Operating lease liability (note 7) | 1,532 | 1,369 |
| Total current liabilities | 41,792 | 35,590 |
| Operating lease liability, long-term (note 7) | 6,412 | 7,646 |
| Other liabilities, long-term | 3,199 | — |
| Total liabilities | 51,403 | 43,236 |
| Shareholders’ equity: | ||
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 80,010,790 (December 31, 2024 - 76,416,086) (note 9) | $1,598,571 | $1,456,836 |
| Additional paid-in capital | 228,234 | 199,149 |
| Accumulated deficit | (1,245,380) | (899,470) |
| Accumulated other comprehensive income (loss) | 335 | (1,612) |
| Total shareholders' equity | $581,760 | $754,903 |
| Total liabilities and shareholders’ equity | $633,163 | $798,139 |
| Commitments and contingencies (note 12) | ||
| Subsequent event (note 9) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.